ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

A New Program, Established by The Claims Conference and Funded by The German Government, Will Ensure Holocaust Survivors Globally Have the Means to Get To COVID-19 Vaccine Sites

Qure4u's holistic patient engagement platform and contactless "digital front door" offers patients and providers a scalable, EHR-embedded platform that supports the entire care journey.